[1]
|
Azim, H.A., Shohdy, K.S., Elghazawy, H., et al. (2022) Programmed Death-Ligand 1 (PD-L1) Expression Predicts Re-sponse to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Bi-omarkers, 27, 764-772. https://doi.org/10.1080/1354750X.2022.2112614
|
[2]
|
Ji, P., Gong, Y. and Hu, X. (2019) Role of PD-1/PD-L1 in Microenvironment of Breast Cancer. Chinese Journal of Oncology, 41, 401-405.
|
[3]
|
Yuan, K.Y., Wu, J.P., Zhao, Y.J., et al. (2022) Consistent Expression of PD-L1 in Tumor Microenvironment with Peripheral PD-1/PD-L1 in Circulating T Lymphocytes of Operable Breast Cancer: A Diagnostic Test. Diagnostic Pathology, 17, Article No. 68. https://doi.org/10.1186/s13000-022-01249-w
|
[4]
|
Oner, G., Önder, S., Karatay, H., et al. (2021) Clinical Impact of PD-L1 Expression in Triple-Negative Breast Cancer Patients with Residual Tumor Burden after Neo-adjuvant Chemotherapy. World Journal of Surgical Oncology, 19, Article No. 264. https://doi.org/10.1186/s12957-021-02361-9
|
[5]
|
Mori, H., Kubo, M., Yamaguchi, R., et al. (2017) The Combina-tion of PD-L1 Expression and Decreased Tumor-Infil- trating Lymphocytes Is Associated with a Poor Prognosis in Tri-ple-Negative Breast Cancer. Oncotarget, 8, 15584-15592. https://doi.org/10.18632/oncotarget.14698
|
[6]
|
Chu, J., Yeo, M.-K., Lee, S.H., et al. (2022) Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients with Triple-Negative Breast Cancer. In Vivo, 36, 2890-2898.
https://doi.org/10.21873/invivo.13030
|
[7]
|
Purwanto, I., Heriyanto, D.S., Ghozali, A., et al. (2020) Overexpres-sion of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer. World Journal of Oncology, 11, 216-222. https://doi.org/10.14740/wjon1302
|
[8]
|
Zhang, M.H., Sun, H.B., Zhao, S., et al. (2017) Expression of PD-L1 and Prognosis in Breast Cancer: A Meta-Analysis. Oncotarget, 8, 31347-31354. https://doi.org/10.18632/oncotarget.15532
|
[9]
|
Yoshikawa, K., Ishida, M., Yanai, H., et al. (2021) Prognostic Significance of PD-L1-Positive Cancer-Associated Fibroblasts in Patients with Triple-Negative Breast Cancer. BMC Cancer, 21, Article No. 239.
https://doi.org/10.1186/s12885-021-07970-x
|
[10]
|
Yazaki, S., Shimoi, T., Yoshida, M., et al. (2023) Integrative Prognostic Analysis of Tumor-Infiltrating Lymphocytes, CD8, CD20, Programmed Cell Death-Ligand 1, and Tertiary Lymphoid Structures in Patients with Early-Stage Triple- Negative Breast Cancer Who Did Not Receive Adjuvant Chem-otherapy. Breast Cancer Research and Treatment, 197, 287-297. https://doi.org/10.1007/s10549-022-06787-x
|
[11]
|
Cerbelli, B., Pernazza, A., Botticelli, A., et al. (2017) PD-L1 Ex-pression in TNBC: A Predictive Biomarker of Responseto Neoadjuvant Chemotherapy? Biomed Research International, 2017, Article ID: 1750925.
https://doi.org/10.1155/2017/1750925
|
[12]
|
Guo, L., Li, W.B., Zhu, X.X., et al. (2016) PD-L1 Expression and CD274 Gene Alteration in Triple-Negative Breast Cancer: Implication for Prognostic Biomarker. SpringerPlus, 5, Article No. 805.
https://doi.org/10.1186/s40064-016-2513-x
|
[13]
|
Stovgaard, E.S., Bokharaey, M., List-Jensen, K., et al. (2020) PD-L1 Diagnostics in the Neoadjuvant Setting: Implications of Intratumoral Heterogeneity of PD-L1 Expression in Triple Negative Breast Cancer for Assessment in Small Biopsies. Breast Cancer Research and Treatment, 181, 553-560. https://doi.org/10.1007/s10549-020-05655-w
|
[14]
|
Tomioka, N., Azuma, M., Ikarashi, M., et al. (2018) The Ther-apeutic Candidate for Immune Checkpoint Inhibitors Elucidated by the Status of Tumor-Infiltrating Lymphocytes (TILs) and Programmed Death Ligand 1 (PD-L1) Expression in Triple Negative Breast Cancer (TNBC). Breast Cancer, 25, 34-42. https://doi.org/10.1007/s12282-017-0781-0
|
[15]
|
Wang, H., Ding, X.-H., Liu, C.-L., et al. (2023) Genomic Alterations Impacting Tumor-Infiltrating Lymphocytes and PD-L1 Expression Patterns in Triple-Negative Breast Cancer. JNCI-Journal of the National Cancer Institute, djad154.
https://doi.org/10.1093/jnci/djad154
|
[16]
|
Pan, B.J., Xu, C., Ping, G.Q., et al. (2017) Correlation Analysis of PD-L1 Expression and Prognosis in Triple-Negative Breast Cancers. Chinese Journal of Pathology, 46, 822-826.
|
[17]
|
Dieci, M.V., Tsvetkova, V., Griguolo, G., et al. (2020) Integration of Tumour Infiltrating Lymphocytes, Programmed Cell-Death Ligand-1, CD8 and FOXP3 in Prognostic Models for Triple-Negative Breast Cancer: Analysis of 244 Stage I-III Patients Treated with Standard Therapy. European Journal of Cancer, 136, 7-15.
https://doi.org/10.1016/j.ejca.2020.05.014
|
[18]
|
Suzuki, K., Ohe, R., Kabasawa, T., et al. (2023) Histological Spatial Analysis on the Induction of PD-L1+ Macrophages by CD8+ T Cells at the Marginal Microenvironment of Tri-ple-Negative Breast Cancer. Breast Cancer, 30, 1094-1104. https://doi.org/10.1007/s12282-023-01507-9
|
[19]
|
Lotfinejad, P., Kazemi, T., Mokhtarzadeh, A., et al. (2020) PD-1/PD-L1 Axis Importance and Tumor Microenvironment Immune Cells. Life Sciences, 259, Article ID: 118297. https://doi.org/10.1016/j.lfs.2020.118297
|
[20]
|
Zhang, M.L., Song, J., Yang, H.G., et al. (2022) Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Acta Oncologica, 61, 1105-1115.
https://doi.org/10.1080/0284186X.2022.2106795
|